Cargando…
Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec(®); Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic a...
Autores principales: | Annaberdyev, Shohrat, Gibbons, Joseph, Hardacre, Jeffrey M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661077/ https://www.ncbi.nlm.nih.gov/pubmed/19291285 http://dx.doi.org/10.1186/1477-7819-7-30 |
Ejemplares similares
-
Dramatic response of an inoperable Merkel cell carcinoma with imatinib
por: Frenard, Cecile, et al.
Publicado: (2016) -
Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis
por: Niikura, Ryota, et al.
Publicado: (2016) -
Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib
por: Jiang, Xiaoyin, et al.
Publicado: (2015) -
Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors
por: Coleman, Emily, et al.
Publicado: (2019) -
Imatinib therapy for a patient with metastasis of colonic gastrointestinal stromal tumor: report of a case
por: Okamura, Takuma, et al.
Publicado: (2013)